Home » Stocks » TARO

Taro Pharmaceutical Industries Ltd. (TARO)

Stock Price: $71.46 USD -0.04 (-0.06%)
Updated Mar 4, 2021 1:15 PM EST - Market open
Market Cap 2.74B
Revenue (ttm) 575.56M
Net Income (ttm) -302.67M
Shares Out 38.25M
EPS (ttm) -7.91
PE Ratio n/a
Forward PE 18.38
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $71.46
Previous Close $71.50
Change ($) -0.04
Change (%) -0.06%
Day's Open 71.28
Day's Range 71.12 - 72.69
Day's Volume 9,777
52-Week Range 53.95 - 80.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 4 months ago

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2021 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Taro (TARO) delivered earnings and revenue surprises of 53.25% and 14.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 7 months ago

Taro (TARO) delivered earnings and revenue surprises of -34.48% and -25.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 9 months ago

Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.

Other stocks mentioned: ANIP, LCI, MYL, PFE, TEVA
GuruFocus - 9 months ago

Value investors like companies with strong balance sheets and no debt; it means there are no worries about the company going broke or getting into serious financial trouble.

Seeking Alpha - 9 months ago

Taro Pharmaceutical Industries Ltd.'s (TARO) CEO Uday Baldota on Q4 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Taro (TARO) delivered earnings and revenue surprises of -7.19% and 3.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 1 year ago

Taro Pharmaceutical Industries Ltd (NYSE: TARO) former Vice President of Sales and Marketing Ara Aprahamian has been indicted by the Justice Department for price-fixing and bid-rigging on Tues...

Zacks Investment Research - 1 year ago

Taro (TARO) delivered earnings and revenue surprises of 14.29% and -14.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Taro (TARO) delivered earnings and revenue surprises of -15.12% and -4.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

Seeking Alpha - 1 year ago

Taro has inherited a top tier balance sheet due to management's refusal to engage in LBOs during the drug acquisition bubble of 2014-2015.

Seeking Alpha - 1 year ago

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Taro (TARO) delivered earnings and revenue surprises of -32.74% and -5.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

About TARO

Taro Pharmaceutical Industries, a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antip... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1959
CEO
Uday Baldota
Employees
1,464
Stock Exchange
NYSE
Ticker Symbol
TARO
Full Company Profile

Financial Performance

In 2019, TARO's revenue was $644.77 million, a decrease of -3.75% compared to the previous year's $669.89 million. Earnings were $244.24 million, a decrease of -13.32%.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for TARO stock is "Buy" and the 12-month stock price forecast is 81.00.

Price Target
$81.00
Analyst Consensus: Buy